DBV Technologies (DBV.PA) Surges Over 15% in Premarket Trading on Strong Efficacy Data for Viaskin Peanut in Toddlers

Gelonghui June 8th :: DBV Technologies (DBV.PA) rose over 15% pre-market, trading at $1.77. The company announced on Tuesday that its drug Viaskin Peanut showed significant therapeutic effects in children aged 1 to 3 with peanut allergies, achieving the primary efficacy endpoint in late-stage trials.